Fennec Pharmaceuticals (FENC) CCO receives 168 vested shares

Rhea-AI Filing Summary

Fennec Pharmaceuticals reported that Chief Commercial Officer Terry L. Evans acquired 168 Common Shares on July 31, 2026 through the release of restrictions on shares originally awarded 3/28/2025. After this vesting event, Evans directly holds 21,351 Common Shares, with no Rule 10b5-1 trading plan indicated.

Insider Trade Summary

Net Buyer: 168 shares

Net Buy 1 txn

Insider Evans Terry L

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	168	$0.00	$0.00

Holdings After Transaction: Common Shares — 21,351 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 3/28/2025.

Key Figures

Shares acquired: 168 Common Shares Total holdings after transaction: 21,351 Common Shares Transaction price per share: $0.0000 per share +1 more

4 metrics

Shares acquired 168 Common Shares Grant/award acquisition on July 31, 2026

Total holdings after transaction 21,351 Common Shares Direct ownership following July 31, 2026 release

Transaction price per share $0.0000 per share Stated value for vested shares

Award date of restricted shares 3/28/2025 Original award date referenced in the footnote

Key Terms

shares released from restriction, Common Shares, Chief Commercial Officer

3 terms

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

Common Shares financial

"A non-derivative transaction in security titled Common Shares."

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Chief Commercial Officer other

"Evans Terry L serves as Chief Commercial Officer."

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 04:06 PM Accepted by SEC EDGAR 08/03/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transaction did FENC report for Terry L. Evans?

Terry L. Evans received 168 Common Shares of Fennec Pharmaceuticals on July 31, 2026, through the release of restrictions on previously awarded shares, increasing his direct ownership as part of his equity-based compensation.

How many FENC shares does Terry L. Evans own after this transaction?

After the reported vesting, Terry L. Evans directly holds 21,351 Common Shares of Fennec Pharmaceuticals. This figure reflects his ownership immediately following the release of restrictions on the 168 previously awarded shares.

Was Terry L. Evans’s FENC share acquisition under a Rule 10b5-1 plan?

The report indicates no Rule 10b5-1 trading plan for this transaction. The document-level 10b5-1 checkbox is not marked, and the related footnote describes only the release of restricted shares originally awarded on 3/28/2025.

What was the price per share for the FENC shares acquired by Terry L. Evans?

The 168 Fennec common shares are reported at $0.0000 per share, consistent with a restricted stock vesting rather than an open-market purchase. The value reflects an equity award release instead of a cash-funded transaction.

What is the nature of the FENC shares released to Terry L. Evans?

The 168 shares represent shares released from restriction from an equity award granted on 3/28/2025. This indicates a vesting event where previously granted restricted shares became freely owned by Terry L. Evans.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans Terry L

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	07/31/2026		A		168	A	$0	21,351	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Terry Evans	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)